Abstract
As a partial agonist at the glycine site of the NMDA receptor, D-cycloserine (DCS) has been viewed as lacking potency to fully test the NMDA receptor hypofunction theory of schizophrenia. However, findings of full agonist activity at a subset of NMDA receptors that may have particular relevance to schizophrenia, plus a growing body of evidence demonstrating enhancement of learning and neuroplasticity in animal models, suggest novel therapeutic strategies with DCS in schizophrenia. Preliminary studies with once-weekly administration have supported this potential new role for DCS in schizophrenia by demonstrating benefit for negative symptoms, memory consolidation, and facilitation of cognitive behavioral therapy for delusions.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Affect / drug effects
-
Affect / physiology
-
Animals
-
Arousal / drug effects
-
Arousal / physiology
-
Brain / drug effects
-
Brain / physiopathology
-
Cognitive Behavioral Therapy
-
Combined Modality Therapy
-
Cycloserine / pharmacology*
-
Cycloserine / therapeutic use*
-
Disability Evaluation
-
Disease Models, Animal
-
Drug Administration Schedule
-
Humans
-
Learning / drug effects*
-
Learning / physiology*
-
Magnetic Resonance Imaging
-
Memory / drug effects*
-
Memory / physiology*
-
Memory, Short-Term / drug effects
-
Memory, Short-Term / physiology
-
Motivation / drug effects
-
Motivation / physiology
-
Neuronal Plasticity / drug effects*
-
Neuronal Plasticity / physiology*
-
Quality of Life / psychology
-
Receptors, N-Methyl-D-Aspartate / drug effects*
-
Receptors, N-Methyl-D-Aspartate / physiology*
-
Schizophrenia / diagnosis
-
Schizophrenia / drug therapy*
-
Schizophrenia / physiopathology*
-
Schizophrenic Psychology*
Substances
-
Receptors, N-Methyl-D-Aspartate
-
Cycloserine